Rising Prevalence Of Cardiovascular Diseases Propels Growth In The Calcium Channel Blocker Market: The Driving Engine Behind Calcium Channel Blocker Market Evolution in 2025

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Calcium Channel Blocker Market Size Growth Forecast: What to Expect by 2025?
In recent times, the size of the calcium channel blocker market has seen robust growth. A rise from $15.56 billion in 2024 to $16.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.8% is predicted. This growth experienced in the historical period may be credited to factors like the increasing occurrences of cardiovascular diseases, an aging population, progress in medical research, lifestyle changes, and heightened awareness.

How Will the Calcium Channel Blocker Market Size Evolve and Grow by 2029?
Anticipations show a robust growth in the calcium channel blocker market in the coming years, with estimations suggesting a value of $22.07 billion in 2029 and a compound annual growth rate (CAGR) of 7.4%. This upward trend in projections can be credited to factors such as the escalating global incidence of cardiovascular ailments, the emergence of personalized medicine, wider access to healare services, expansion of medical indications, as well as regulatory nods and widening market landscapes. The forecast period will see market advancement, technology upgrades, evolving regulatory framework, competitive assessments, evolving patient choices and heightened awareness as the major market trends.

View the full report here:
https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

What Drivers Are Propelling the Growth of Calcium Channel Blocker Market Forward?
The rise in incidences of cardiovascular diseases is projected to fuel the expansion of the calcium channel blocker market. Cardiovascular ailment is a broad term that encompasses conditions impacting the heart and blood vessels. Calcium channel blockers (CCBs) serve to minimize the likelihood of heart failure and stroke. As such, a greater prevalence of cardiovascular diseases reciprocates into a higher demand for calcium channel blockers. As per an August 2022 report by the American College of Cardiology, a non-profit medical organization from the United States, it is predicted that all four cardiovascular risk elements will see an upsurge between 2025 and 2060. The most significant proportional increase is expected in diabetes, with a rise of 39.3% amounting to 55 million individuals, trailed by dyslipidemia (27.6% amounting to 126 million), hypertension (25.1% amounting to 162 million), and obesity (18.3% amounting to 126 million). The study also noted the most substantial anticipated increases in cardiovascular disease rates were in stroke (33.8% amounting to 15 million) and heart failure (33.4% amounting to 13 million), with ischemic heart disease (30.7% amounting to 29 million) and heart attack (16.9% amounting to 16 million) following next. Hence, the escalating prevalence of cardiovascular diseases is steering the advancement of the calcium channel blocker market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

Which Emerging Trends Are Transforming the Calcium Channel Blocker Market in 2025?
In the calcium channel blocker market, the main trend gaining traction is product innovation. Major firms in this market are concentrated on creating innovative products to maintain their market standing. For example, in June 2022, U.S based pharmaceutical manufacturer, CMP Pharma, introduced Norliqva, the first and exclusive oral liquid solution of the besylate salt of amlodipine, which is a long-lasting calcium channel blocker. The uniqueness of Norliqva lies in its liquid form which is utilized for the treatment of high blood pressure in individuals above 6 years of age. This eliminates the challenges and inconsistencies associated with crushing or manufacturing amlodipine tablets, providing consistent dosage and bioequivalence. Norliqva is designed specifically for a segment of patients who need amlodipine but struggle with swallowing or cannot swallow at all.

What Are the Key Segments in the Calcium Channel Blocker Market?
The calcium channel blocker market covered in this report is segmented -

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes
2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine
2) By Benzodiazepine: Diazepam
3) By Phenylalkylamine: Verapamil
4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

Who Are the Key Players Shaping the Calcium Channel Blocker Market's Competitive Landscape?
Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

What Geographic Markets Are Powering Growth in the Calcium Channel Blocker Market?
North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9428

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.